IN VIVO CONSIDERATIONS
 Release rate = elimination rate, which depends on Kel, Vd, T/P ratio, and Css,des  Moderate rate constant for absorption & excretion  May need priming IR dose  2<t 1/2 <8  Treats chronic (not acute) diseases, e.g.
hypertension not antibiotics  Problems:
o Shouldn't induce/inhibit enzyme synthesis o Variable blood levels due to metabolism o Slow/variable absorption o Narrow therapeutic window DELAYED RELEASE  Enteric coating that has a pKa of 5 so that it doesn't dissolve in the stomach, but when it reaches the small intestine of pH=7, then it releases drug  Zerofull release  Take at nightmorning blood levels  Coating formulation has cellulosic polymer w/pH sensitive functional group  May also function as repeat action 
PHARMACIST COUNSELING POINTS
 Don't intermittently use IR products  Don't change to another ER unless equivalent bioavailability ensured  Don't crush/chew w/o careful review  Nasogastric tube patients can use pelletized products  "Ghost" shells from hydrophobic matrix products might be visible in stool
